Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
Motohiro FujiwaraTakeshi YuasaYoshinobu KomaiNoboru NumaoShinya YamamotoIwao FukuiJunji YonesePublished in: Targeted oncology (2021)
Both the survival period and risk factors were extracted from a relatively long-term observation period. Since enzalutamide was approved for administration to patients with castration-sensitive prostate cancer earlier this year (2020), we believe that the data presented here will be useful for both physicians and patients in clinical practice.
Keyphrases
- prognostic factors
- prostate cancer
- risk factors
- radical prostatectomy
- squamous cell carcinoma
- end stage renal disease
- small cell lung cancer
- clinical practice
- primary care
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- electronic health record
- big data
- patient reported outcomes
- artificial intelligence
- data analysis